Janjigian, Y. Y., Shoji, H., Kowalczyk, A., Rha, S. Y., Pietrantonio, F., Shitara, K., Ferrándiz, A. C., Laarhoven, H. W. V., Liu, T., Karaszewska, B., Lee, K., Abdalla, K. C., Chen, E. X., Asselah, J., Limon, M. L., Scott, M., Lloyd, C., Nwazue, E., Rabbie, R., Lee, J. (2026). First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4022